Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the longevity research company, has been invited to present results from its SLAB clinical study at the Animal Longevity Summit in Toronto on 1 to 2 October.
The study evaluates the company's centenarian SIRT6 gene therapy in aged beagles, targeting age-related decline in companion animals.
Genflow said the presentation would provide one of the most comprehensive datasets yet from its veterinary programme.
The SLAB study began in March 2025 and concludes in June 2026.